In contrast, the PLX-NP@Gel+P-aPD-1 group showed a 1.6-fold greater number of CD8+ T cells compared with the PLX-NP@Gel+aPD-1 group, which could be attributed to the increased pharmacokinetics and tumor-selective accumulation of aPD-1 mediated by platelets. Here, CD8A is linked to neoplasm.